Omentin protects H9c2 cells against docetaxel cardiotoxicity.
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2019
2019
Historique:
received:
06
09
2018
accepted:
08
02
2019
entrez:
23
2
2019
pubmed:
23
2
2019
medline:
22
11
2019
Statut:
epublish
Résumé
Association between obesity and cardiovascular diseases is well known, however increased susceptibility of obese patients to develop several cancer types is not so commonly known. Current data suggest that poorer overall survival in cancer patients might be associated to non-cancer-related causes such as higher risk of cardiotoxicity in obese patients treated with chemotherapeutic agents. Omentin, a novel adipokine decreased in obesity, is actually in the spotlight due to its favourable effects on inflammation, glucose homeostasis and cardiovascular diseases. Also, recent data showed that in vitro anthracycline-induced cardiomyocyte apoptosis is counteracted by omentin suggesting its cardioprotective role. Our aim was to evaluate omentin effects against docetaxel toxicity. Our data indicate that omentin inhibits docetaxel-induced viability loss and that increased viability is associated to decreased caspase-3 expression and cell death. Although omentin reduces NOX4 expression, it failed to reduce docetaxel-induced reactive oxygen species production. Our results indicate that omentin decreases docetaxel-induced endoplasmic reticulum stress, suggesting that cardioprotective role might be associated to ERS inhibition. These data suggest that omentin treatment may contribute to decrease susceptibility to DTX-induced cardiotoxicity.
Sections du résumé
BACKGROUND
Association between obesity and cardiovascular diseases is well known, however increased susceptibility of obese patients to develop several cancer types is not so commonly known. Current data suggest that poorer overall survival in cancer patients might be associated to non-cancer-related causes such as higher risk of cardiotoxicity in obese patients treated with chemotherapeutic agents. Omentin, a novel adipokine decreased in obesity, is actually in the spotlight due to its favourable effects on inflammation, glucose homeostasis and cardiovascular diseases. Also, recent data showed that in vitro anthracycline-induced cardiomyocyte apoptosis is counteracted by omentin suggesting its cardioprotective role.
OBJECTIVE
Our aim was to evaluate omentin effects against docetaxel toxicity.
RESULTS
Our data indicate that omentin inhibits docetaxel-induced viability loss and that increased viability is associated to decreased caspase-3 expression and cell death. Although omentin reduces NOX4 expression, it failed to reduce docetaxel-induced reactive oxygen species production. Our results indicate that omentin decreases docetaxel-induced endoplasmic reticulum stress, suggesting that cardioprotective role might be associated to ERS inhibition.
CONCLUSION
These data suggest that omentin treatment may contribute to decrease susceptibility to DTX-induced cardiotoxicity.
Identifiants
pubmed: 30794687
doi: 10.1371/journal.pone.0212782
pii: PONE-D-18-26197
pmc: PMC6386316
doi:
Substances chimiques
Cytokines
0
Lectins
0
Reactive Oxygen Species
0
omentin protein, rat
0
Docetaxel
15H5577CQD
NADPH Oxidase 4
EC 1.6.3.-
Nox4 protein, rat
EC 1.6.3.-
Casp3 protein, rat
EC 3.4.22.-
Caspase 3
EC 3.4.22.-
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0212782Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
Crit Rev Oncol Hematol. 2013 Oct;88(1):75-86
pubmed: 23522920
Cell Signal. 2016 Mar;28(3):190-203
pubmed: 26631573
Apoptosis. 2008 Dec;13(12):1505-12
pubmed: 18989785
CA Cancer J Clin. 2017 Sep;67(5):378-397
pubmed: 28763097
PLoS One. 2014 Aug 14;9(8):e103109
pubmed: 25121735
J Biol Chem. 2012 Jan 2;287(1):408-17
pubmed: 22081609
Cancer Chemother Pharmacol. 2015 Dec;76(6):1297-307
pubmed: 26515054
JCO Clin Cancer Inform. 2017 Nov;1:1-12
pubmed: 30657376
Nat Rev Clin Oncol. 2015 Dec;12(12):718-31
pubmed: 26462128
Clin Exp Pharmacol Physiol. 2007 Jan-Feb;34(1-2):81-7
pubmed: 17201740
Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2017 Mar;161(1):31-40
pubmed: 28228651
Am J Physiol Heart Circ Physiol. 2006 Sep;291(3):H1411-20
pubmed: 16617122
Sci Rep. 2016 Apr 07;6:24217
pubmed: 27052593
In Vivo. 2013 May-Jun;27(3):321-32
pubmed: 23606687
J Biol Chem. 2011 Sep 16;286(37):32790-800
pubmed: 21784858
Circ Res. 1991 Dec;69(6):1476-86
pubmed: 1683272
Diabetes. 2007 Jun;56(6):1655-61
pubmed: 17329619
J Cancer. 2016 Jan 01;7(2):207-13
pubmed: 26819645
Nat Prod Rep. 2014 Mar;31(3):335-55
pubmed: 24481420
Int J Oncol. 2016 Jun;48(6):2330-8
pubmed: 27082738
Cytokine Growth Factor Rev. 2014 Aug;25(4):483-7
pubmed: 25066649
Hematology. 2008 Aug;13(4):215-23
pubmed: 18796247
Cell Death Differ. 2010 Jun;17(6):1003-10
pubmed: 20057500
Am J Physiol Heart Circ Physiol. 2014 Jun 15;306(12):H1714-9
pubmed: 24727494
Lancet. 2008 Feb 16;371(9612):569-78
pubmed: 18280327
J Liposome Res. 2009;19(2):122-30
pubmed: 19235543
J Nephrol. 2017 Feb;30(1):1-10
pubmed: 28214961
Clin Transl Oncol. 2017 Sep;19(9):1067-1078
pubmed: 28342058
Int J Cardiol. 2013 Sep 30;168(2):680-7
pubmed: 23639459
Nature. 2016 Jan 21;529(7586):326-35
pubmed: 26791723
Toxicol Sci. 2015 May;145(1):59-67
pubmed: 25634538
J Am Coll Cardiol. 2014 Jun 24;63(24):2722-33
pubmed: 24768874
Radiats Biol Radioecol. 2003 Nov-Dec;43(6):640-6
pubmed: 14963930
Can J Cardiol. 2016 Jul;32(7):900-7
pubmed: 27343745
Eur J Pharmacol. 2012 Jul 5;686(1-3):116-23
pubmed: 22554771
Lancet. 2014 Mar 15;383(9921):999-1008
pubmed: 24084292
Curr Opin Cell Biol. 1999 Feb;11(1):81-94
pubmed: 10047525
Cancer Chemother Pharmacol. 2016 Apr;77(4):777-85
pubmed: 26914236
Toxicol Appl Pharmacol. 2008 Sep 15;231(3):413-22
pubmed: 18674790
Oncogenesis. 2017 Aug 28;6(8):e373
pubmed: 28846078
Gen Physiol Biophys. 2013 Dec;32(4):535-43
pubmed: 24067283
CA Cancer J Clin. 2016 Jul;66(4):309-25
pubmed: 26919165
J Cardiovasc Med (Hagerstown). 2016 May;17 Suppl 1 Special issue on Cardiotoxicity from Antiblastic Drug:e84-e92
pubmed: 27755246
Clin Chim Acta. 2015 Aug 25;448:98-106
pubmed: 26079253
Biochem Biophys Res Commun. 2015 Feb 20;457(4):602-7
pubmed: 25600813
Biochim Biophys Acta. 2015 Feb;1853(2):276-84
pubmed: 25450968
Brain Res Bull. 2017 Apr;130:27-35
pubmed: 28017783
Apoptosis. 2017 May;22(5):647-661
pubmed: 28229251
J Biochem. 2012 Mar;151(3):217-9
pubmed: 22210905
N Engl J Med. 2003 Apr 24;348(17):1625-38
pubmed: 12711737
Biochem J. 2010 Jan 27;426(1):43-53
pubmed: 19925454
Prostate. 2010 Mar 1;70(4):433-42
pubmed: 19866475
Int J Mol Sci. 2017 Apr 05;18(4):
pubmed: 28379196
Biomed Pharmacother. 2005 Oct;59 Suppl 2:S306-10
pubmed: 16507399
J Clin Oncol. 2016 Sep 10;34(26):3157-65
pubmed: 27458291